Development of Pharmacotherapies for the Treatment of Sarcopenia
- PMID: 31237312
- DOI: 10.14283/jfa.2019.11
Development of Pharmacotherapies for the Treatment of Sarcopenia
Abstract
Sarcopenia, the associated loss of skeletal muscle mass and strength and impaired physical function seen with aging, is a growing, global public health challenge in need of accepted, proven treatments that address the needs of a broad range of older adults. While exercise, primarily resistance training, and increased dietary protein have been shown to delay and even reverse losses in muscle mass, strength and physical function seen with aging, proven treatments that are accessible globally, cost effective and sustainable by patients are needed. While no drug has yet demonstrated the substantial safety and clinical value needed to be the first pharmacological therapy registered for muscle wasting or sarcopenia, the field is active. Several approaches to treating the muscle loss and subsequent functional decline are being studied in a variety of patient populations across every continent. We provide a review of the leading programs and approaches and available findings from recent studies. In addition, we briefly discuss several related issues needed to facilitate the development of a safe and efficacious pharmacotherapeutic that could be used as part of a treatment plan for older men and women with sarcopenia.
Keywords: Sarcopenia; aging; functional impairment; pharmacotherapy; skeletal muscle.
Conflict of interest statement
Both authors are full-time employees of Novartis Institutes for BioMedical Research
Similar articles
-
Current pharmacotherapies for sarcopenia.Expert Opin Pharmacother. 2019 Sep;20(13):1645-1657. doi: 10.1080/14656566.2019.1622093. Epub 2019 May 23. Expert Opin Pharmacother. 2019. PMID: 31120352 Review.
-
Protein and exercise in the prevention of sarcopenia and aging.Nutr Res. 2017 Apr;40:1-20. doi: 10.1016/j.nutres.2017.01.001. Epub 2017 Jan 16. Nutr Res. 2017. PMID: 28473056 Review.
-
Lost in translation: challenges of current pharmacotherapy for sarcopenia.Trends Mol Med. 2024 Nov;30(11):1047-1060. doi: 10.1016/j.molmed.2024.05.016. Epub 2024 Jun 15. Trends Mol Med. 2024. PMID: 38880726 Review.
-
Beta-Hydroxy-Beta-Methyl Butyrate (HMB): From Experimental Data to Clinical Evidence in Sarcopenia.Curr Protein Pept Sci. 2018;19(7):668-672. doi: 10.2174/1389203718666170529105026. Curr Protein Pept Sci. 2018. PMID: 28554316 Review.
-
Treating sarcopenia in older and oldest old.Curr Pharm Des. 2015;21(13):1715-22. doi: 10.2174/1381612821666150130122032. Curr Pharm Des. 2015. PMID: 25633117 Review.
Cited by
-
Editorial: The relationship between sarcopenia and metabolic diseases: Its formation mechanism and intervention means.Front Endocrinol (Lausanne). 2022 Aug 25;13:972238. doi: 10.3389/fendo.2022.972238. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36093114 Free PMC article. No abstract available.
-
Gaining muscle mass in COPD: a work in progress.ERJ Open Res. 2023 Jul 31;9(4):00336-2023. doi: 10.1183/23120541.00336-2023. eCollection 2023 Jul. ERJ Open Res. 2023. PMID: 37529635 Free PMC article.
-
A Bioassay-Guided Fractionation of Rosemary Leaf Extract Identifies Carnosol as a Major Hypertrophy Inducer in Human Skeletal Muscle Cells.Nutrients. 2021 Nov 23;13(12):4190. doi: 10.3390/nu13124190. Nutrients. 2021. PMID: 34959741 Free PMC article.
-
Myostatin and Follistatin-New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications.Biomedicines. 2021 Sep 23;9(10):1301. doi: 10.3390/biomedicines9101301. Biomedicines. 2021. PMID: 34680417 Free PMC article. Review.
-
Emerging molecular mediators and _targets for age-related skeletal muscle atrophy.Transl Res. 2020 Jul;221:44-57. doi: 10.1016/j.trsl.2020.03.001. Epub 2020 Mar 10. Transl Res. 2020. PMID: 32243876 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
